{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:03:01Z","timestamp":1784952181365,"version":"3.55.0"},"reference-count":15,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Einstein (S\u00e3o Paulo)"],"abstract":"<jats:p>ABSTRACT Acute myeloid leukemia is a hematopoietic stem cell neoplastic disease associated with high morbidity and mortality. The presence of FLT3 internal tandem duplication mutations leads to high rates of relapse and decreased overall survival. Patients with FLT3 internal tandem duplication are normally treated with hematopoietic stem cell transplantation in first complete remission. Nevertheless, the incidence of post-transplant relapse is considerable in this group of patients, and the management of this clinical condition is challenging. The report describes the outcomes of patients with FLT3 internal tandem duplication positive acute myeloid leukemia who relapsed after allogeneic hematopoietic stem cell transplantation and were treated with the combination of re-induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Three cases are described and all patients achieved prolonged complete remission with the combined therapy. The combination of induction chemotherapy followed by donor lymphocyte infusion, and the maintenance with azacitidine and sorafenib can be effective approaches in the treatment of post-hematopoietic stem cell transplant and relapsed FLT3 internal tandem duplication positive acute myeloid leukemia patients. This strategy should be further explored in the context of clinical trials.<\/jats:p>","DOI":"10.1590\/s1679-45082017rc3784","type":"journal-article","created":{"date-parts":[[2017,7,22]],"date-time":"2017-07-22T23:38:44Z","timestamp":1500766724000},"page":"355-358","source":"Crossref","is-referenced-by-count":10,"title":["Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases"],"prefix":"10.1590","volume":"15","author":[{"given":"Paulo Vidal","family":"Campregher","sequence":"first","affiliation":[{"name":"Hospital Israelita Albert Einstein,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Renan Pinto de","family":"Mattos","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Aur\u00e9lio","family":"Salvino","sequence":"additional","affiliation":[{"name":"Hospital S\u00e3o Rafael,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Pires de Souza","family":"Santos","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner H","year":"2010","journal-title":"Blood"},{"issue":"20","key":"ref2","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system","volume":"29","author":"R\u00f6llig C","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet S","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.35","article-title":"European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"4","author":"Medeiros BC","year":"2014","journal-title":"Blood Cancer J"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine JE","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder T","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"Metzelder SK","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2011.07.011","article-title":"Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib","volume":"17","author":"Sharma M","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bbmt.2007.06.007","article-title":"Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"13","author":"Mielcarek M","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ijc.28362","article-title":"Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity","volume":"134","author":"Chen ML","year":"2014","journal-title":"Int J Cancer"},{"issue":"15","key":"ref11","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1182\/blood-2010-06-291104","article-title":"Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation","volume":"116","author":"Yokoyama H","year":"2010","journal-title":"Blood"},{"issue":"26","key":"ref12","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","article-title":"Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation","volume":"113","author":"Metzelder S","year":"2009","journal-title":"Blood"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder T","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"ref14","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear OC","year":"2012","journal-title":"Blood"},{"issue":"23","key":"ref15","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation","volume":"121","author":"Ravandi F","year":"2013","journal-title":"Blood"}],"container-title":["Einstein (S\u00e3o Paulo)"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/eins\/v15n3\/1679-4508-eins-S1679-45082017RC3784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T02:05:21Z","timestamp":1520301921000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1679-45082017000300355&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,9]]}},"alternative-id":["S1679-45082017000300355"],"URL":"https:\/\/doi.org\/10.1590\/s1679-45082017rc3784","relation":{},"ISSN":["2317-6385","1679-4508"],"issn-type":[{"value":"2317-6385","type":"electronic"},{"value":"1679-4508","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7,24]]}}}